5 not yet recruiting, 4 recruiting. 9 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Not yet recruiting 5, Recruiting 4 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Fallopian Tube Cancers: new trials by email Literature Review of Fallopian Tube Cancers trials Research Report on Fallopian Tube Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 534 | 2026-12-31 | 2026-11-12 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 82 | 2026-07-23 | 2026-11-04 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
| Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2026-03-30 | 2026-03-24 |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers | Phase 1 / Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 60 | 2025-12-10 | 2026-07-13 |
| PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-03-16 |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine Mirvetuximab Soravtansine - Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 2 | Recruiting | AbbVie | 110 | 2025-05-28 | 2026-05-26 |
Fallopian Tube Neoplasms (9) · Ovarian Neoplasms (5) · Carcinoma, Ovarian Epithelial (3)
Adnexal Diseases (9) · Fallopian Tube Diseases (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Neoplasms (9) · Neoplasms by Site (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Gonadal Disorders (6) · Ovarian Diseases (6)
Bevacizumab (2) · Carboplatin (2) · Platinum Compounds (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Atorvastatin (1) · Paclitaxel (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · Standard of Care (1) · anlotinib (1) · irinotecan sucrosofate (1) · mirvetuximab soravtansine (1)
AbbVie (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · N.N. Alexandrov National Cancer Centre (1) · Peking University Cancer Hospital & Institute (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Gynecologic Oncology Group (1) · TORL Biotherapeutics, LLC (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University of Colorado, Denver (1)
China (3) · United States (3) · Australia (1) · Belarus (1) · Belgium (1) · France (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Nicole Marjon, MD, PhD (1) · Ning Li, MD (1)